Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BIAF 
bioAffinity Technologies, Inc. (BIAF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BIAF (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -49.79% | Avg. Invested days 34 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.96M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 1 | Beta 2.55 | 52 Weeks Range 0.16 - 2.26 | Updated Date 08/29/2025 |
52 Weeks Range 0.16 - 2.26 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.1 | Actual -0.17 |
Profitability
Profit Margin -152.18% | Operating Margin (TTM) -198.16% |
Management Effectiveness
Return on Assets (TTM) -110.27% | Return on Equity (TTM) -1802.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6829161 | Price to Sales(TTM) 0.91 |
Enterprise Value 6829161 | Price to Sales(TTM) 0.91 | ||
Enterprise Value to Revenue 0.89 | Enterprise Value to EBITDA -0.21 | Shares Outstanding 28468600 | Shares Floating 22864781 |
Shares Outstanding 28468600 | Shares Floating 22864781 | ||
Percent Insiders 18.89 | Percent Institutions 1.46 |
Upturn AI SWOT
bioAffinity Technologies, Inc.
Company Overview
History and Background
bioAffinity Technologies, Inc. was founded in 2014. It focuses on early cancer detection and targeted therapies using proprietary CyPathu00ae technology. Significant milestones include the commercial launch of CyPathu00ae Lung and ongoing clinical trials.
Core Business Areas
- Early Cancer Detection: Focuses on developing and commercializing non-invasive diagnostics for early detection of lung cancer using sputum samples and flow cytometry.
- Targeted Therapies: Research and development of targeted cancer therapies based on the company's proprietary technology platform.
Leadership and Structure
Maria Zannes serves as the President and CEO. The company has a board of directors and a management team overseeing various aspects of research, development, and commercialization.
Top Products and Market Share
Key Offerings
- CyPathu00ae Lung: A non-invasive diagnostic test for early detection of lung cancer using sputum samples. Market share data is difficult to ascertain due to being a privately traded company with limited disclosures. Competitors include Exact Sciences (EXAS) with their Oncotype DX tests, and various liquid biopsy companies.
Market Dynamics
Industry Overview
The diagnostics industry is experiencing growth, driven by demand for early cancer detection and personalized medicine. The competitive landscape is crowded with established players and emerging startups.
Positioning
bioAffinity is positioned as a provider of non-invasive early cancer detection solutions. Competitive advantages include its proprietary CyPathu00ae technology and focus on lung cancer.
Total Addressable Market (TAM)
The global lung cancer diagnostics market is substantial, estimated in the billions of dollars. bioAffinity aims to capture a portion of this market through its CyPathu00ae Lung test. Because bioAffinity is privately traded, it is difficult to pinpoint the exact TAM percentage share they own.
Upturn SWOT Analysis
Strengths
- Proprietary CyPathu00ae technology
- Non-invasive diagnostic approach
- Focus on early cancer detection
- Experienced management team
Weaknesses
- Limited commercial traction
- Reliance on a single product (CyPathu00ae Lung)
- Need for further clinical validation
- High cash burn rate
Opportunities
- Expanding CyPathu00ae technology to other cancers
- Partnerships with pharmaceutical companies
- Increased awareness of early cancer detection
- Favorable reimbursement policies
Threats
- Competition from established diagnostic companies
- Regulatory hurdles
- Technological advancements in competing diagnostic methods
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- EXAS
- CGDX
Competitive Landscape
bioAffinity faces competition from established diagnostics companies with greater resources and broader product portfolios. The company's competitive advantage lies in its proprietary technology and focus on early lung cancer detection.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is unavailable due to the company's private status.
Future Projections: Future growth projections are based on the success of CyPathu00ae Lung and expansion into other cancer types, but specific analyst estimates are not publicly available.
Recent Initiatives: Recent initiatives include ongoing clinical trials, efforts to expand market access for CyPathu00ae Lung, and development of new diagnostic applications.
Summary
bioAffinity Technologies is a developing diagnostic company focusing on lung cancer detection. Its core strength is its proprietary CyPathu00ae technology but faces financial constraints due to its private status and reliance on a single product. Expanding the platform to other cancers and securing partnerships are crucial for long-term success. The company must also overcome competition and regulatory hurdles in the diagnostics market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- bioAffinity Technologies, Inc. website
- Industry reports
- Competitor analysis
Disclaimers:
This analysis is based on publicly available information and limited due to the company's private status. Market share data is estimated. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About bioAffinity Technologies, Inc.
Exchange NASDAQ | Headquaters San Antonio, TX, United States | ||
IPO Launch date 2022-09-01 | Founder, President, CEO & Director Ms. Maria Zannes J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 57 | Website https://www.bioaffinitytech.com |
Full time employees 57 | Website https://www.bioaffinitytech.com | ||
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.